Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML With a FLT3 Mutation

Approval is based on evidence from the ADMIRAL trial
05 Jun 2019
Haematologic malignancies;  Personalised medicine;  Anticancer agents & Biologic therapy

On 29 May 2019, the US Food and Drug Administration (FDA) approved the addition of overall survival (OS) data in labelling for gilteritinib (XOSPATA, Astellas Pharma US, Inc.), indicated for adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Approval was based on the ADMIRAL trial (NCT02421939), which included 371 adult patients with relapsed or refractory AML having a FLT3 ITD, D835, or I836 mutation by the LeukoStrat® CDx FLT3 Mutation Assay. Patients were randomised (2:1) to receive XOSPATA 120 mg once daily (n=247) over continuous 28-day cycles or prespecified salvage chemotherapy (n=124). Salvage chemotherapy included either intensive cytotoxic chemotherapy or a low-intensity regimen.

For the analysis, OS was measured from the randomisation date until death by any cause. The median OS was 9.3 months for patients receiving gilteritinib and 5.6 months for those on the chemotherapy arm (HR 0.64; 95% CI: 0.49,0.83; 1 sided p-value = 0.0004). The results were consistent in the intensive chemotherapy stratum (HR 0.66; 95% CI: 0.47-0.93) and the low-intensity regimen stratum (HR 0.56; 95% CI: 0.38-0.84).

The adverse reactions occurring in at least 20% of patients receiving gilteritinib were increased transaminase, myalgia/arthralgia, fatigue/malaise, fever, mucositis, oedema, rash, noninfectious diarrhoea, dyspnoea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, and renal impairment. Prescribing information contains a Boxed Warning alerting healthcare professionals and patients about the risk of differentiation syndrome, which may be life-threatening or fatal if not treated.

The recommended gilteritinib dose is 120 mg orally once daily.

Full prescribing information for XOSPATA is available here.

This application used the Real-Time Oncology Review and Assessment Aid pilot programmes. FDA granted this application priority review and fast track designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 05 Jun 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings